Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens
|
|
- Shanon Robinson
- 5 years ago
- Views:
Transcription
1 Clin Chem Lab Med 2012;50(7): by Walter de Gruyter Berlin Boston. DOI /cclm Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens Thomas Strecker1, Jennifer Uhlendorff1, Sandra Diederich1, Claudia Lenz-Bauer2, Heidi Trusheim2, Bernhard Roth 2, Larissa Kolesnikova1, Christian Aepinus 1, Reiner Dornow3, Jens Gerlach4, Mikhail Matrosovich1, Ulrich Valley 2, Markus Eickmann1 and Stephan Becker1, * 1 Institut für Virologie der Philipps-Universität Marburg, Marburg, Germany 2 Novartis Vaccines and Diagnostics GmbH, Marburg, Germany 3 Kreisverwaltung Marburg-Biedenkopf, Fachbereich Gesundheit, Marburg, Germany 4 Regierungspräsidium Gießen, Gießen, Germany Abstract Background: In spring 2009, a new swine-origin influenza A (H1N1) virus emerged in Mexico. During the following weeks the virus spread worldwide, prompting the World Health Organization to declare the first influenza pandemic of the 21st century. Sustained human-to-human transmission and severe disease progression observed in some patients urged public health authorities to respond rapidly to the disease outbreak and vaccine manufacturers to develop pandemic influenza vaccines for mass distribution. With the onset of the pandemic we began to explore the potential of academic/ industrial collaboration to accelerate the production of vaccines during an outbreak of an emerging virus by combining the use of an academic BSL-4 laboratory with the expertise of a commercial vaccine manufacturer. Methods and results: To obtain virus seed stocks used for the production of a vaccine to combat the pandemic H1N influenza virus (), we followed various strategies: (i) optimization of cell culture conditions for growth of wild-type isolates; (ii) classical reassortment of and standard influenza vaccine donor strain PR8; and (iii) generation of corresponding reassortant viruses *Corresponding author: Prof. Stephan Becker, Institut f ü r Virologie, Hans-Meerwein-Str. 2, Marburg, Germany Phone: , Fax: , becker@staff.uni-marburg.de Received October 12, 2011; accepted April 22, 2012 ; previously published online May 23, 2012 using reverse genetics. To ensure a rapid transition to production, the entire potential seed stock development process was carried out in a certified canine kidney suspension cell line (MDCK PF) under Good Manufacturing Practice (GMP) conditions. Conclusions: The outcome of this study indicates that a combination of different experimental strategies is the best way to cope with the need to develop vaccines rapidly in the midst of an emerging pandemic. Keywords: influenza A virus; influenza vaccine development; pandemic; reassortment; reverse genetics. A novel swine-origin H1N1 influenza A virus emerged in humans in April Within weeks the virus spread globally via human-to-human transmission, forcing the World Health Organization (WHO) to declare the first influenza pandemic of the 21st century. During the last decade, concerns about the highly pathogenic avian influenza A (H5N1) virus led the WHO and national health authorities to develop influenza pandemic preparedness and response plans. These involve public health and pharmaceutical interventions that include pandemic influenza vaccine programs in which a clear strategy is suggested regarding how pandemic vaccines should be produced (1, 2). These plans were put in place with the declaration of the 2009 H1N1 pandemic, and the WHO recommended the production of a -specific vaccine to provide protection for the global human population. As it is absolutely essential to react as quickly as possible to emerging pandemics, we explored the possibility of accelerating the process of vaccine production. For this purpose, we established a strategic collaboration between an academic biosafety level 4 (BSL-4) laboratory and an industrial vaccine manufacturer, and evaluated the time required to produce seed virus vaccine candidates using three different experimental approaches. Traditionally, influenza vaccines are produced in embryonated chicken eggs. However, human influenza strains often do not grow well in eggs and thus, the propagation of human isolates in eggs requires the adaptation of the virus, which is, in turn, accompanied by mutations in the envelope glycoproteins hemagglutinin (HA) and neuraminidase (NA). If these mutations lead to changes in immunodominant epitopes, the resulting egg-based vaccine will elicit antibodies that recognise the circulating influenza virus less efficiently (3). In
2 1276 Strecker et al.: Development of vaccine candidates against the event of the emergence of a pandemic caused by avian influenza viruses, some of these strains are highly lethal to chickens and will therefore not grow sufficiently in eggs without prior genetic modification to decrease pathogenicity, thus limiting the rapid use of the egg-based vaccine strategy. Moreover, the potentially limited availability of embryonated chicken eggs may be a critical concern when it comes to meeting global vaccine demands in a pandemic situation. The number of eggs required to produce a certain number of vaccine doses must be calculated approximately five to six months before the start of vaccine production. Therefore, the inability of an egg-based strategy to produce enough doses of required vaccines in a timely manner underscores the urgent need to explore alternative approaches to influenza vaccine production. In recent years, cell culture-based technologies have been developed that have a number of theoretical and practical advantages over the traditional egg-based production of influenza vaccines. The reported benefits of this technology include the easy scalability of continuous cell lines, allowing adaptation to the actual number of vaccine doses required. The use of well-characterized cell lines reduces the risk of introduction of exogenous or endogenous adventitious agents. Additionally, cell-based vaccine manufacturing in closed bioreactors reduces the risk of exogenous microbial contamination. Mammalian cell lines enable the production of influenza vaccines using avian virus strains. Moreover, individuals who are allergic to eggs and egg components can benefit from influenza vaccines derived from cell cultures. As potential vaccine viruses do not require an egg adaptation process for optimal virus growth, cell-based influenza vaccine production not only accelerates the vaccine manufacturing process but, more importantly, also minimizes the selection of virus isolates with reduced immunogenicity and altered antigenicity. Following the identification of the pandemic strain, cell culture-based vaccine production eliminates the long manufacturing lead times and supply-chain vulnerabilities that eggbased production systems are subject to. The new technology could therefore significantly reduce the time from detection of an emerging virus to the delivery of the final vaccine a factor that is particularly important in a pandemic-driven need for influenza vaccines. At present, two approved mammalian cell lines are used for production of influenza virus vaccines: African green monkey kidney (Vero) cells and Madin-Darby canine kidney cells (MDCK). Both cell lines support efficient growth of influenza viruses and are used to produce both seasonal and pandemic influenza vaccines (4 6). In addition, several other continuous cell lines including PER.C6 (derived from human embryonic retina cells), NIH-3T3 (derived from mouse embryo fibroblasts), BHK (baby hamster kidney) and CHO (chinese hamster ovary) have been reported to support replication of influenza viruses, although only PER.C6 cells reached influenza virus titers that are considered commercially relevant. Despite its suitability for industrial-scale manufacturing and regulatory requirements, a cell line destined for the production of human influenza vaccines must be susceptible to a wide range of influenza strains of different origin and thus be capable of propagating these viruses in large quantities. Prior to manufacturing a vaccine designed to combat pandemic influenza viruses, the virus seed stock for large-scale production of the vaccine needs to be prepared on the basis of a virus isolated from clinical material. The development of virus seed stocks from an unknown, potentially highly pathogenic virus is carried out in laboratories equipped to bio-containment level 3 or 4. In our experience, the rapid decontamination procedures and specialized ventilation and air filtration systems present in the Marburg BSL-4 laboratory have proved to be ideally suited for the GMP-compliant production of virus seed stocks. Furthermore, the Marburg laboratory s operating license guarantees a rapid grant of permission to handle pathogens that embody unknown biological risks. The authorization to work with wild-type isolates was granted within 3 days and we received approval from the national authorities to work with the genetically engineered virus within a week. Faced with the global outbreak in April 2009, we explored three different experimental approaches to rapid production of influenza vaccines for combating (Figure 1 A C): (i) wild-type virus isolates were cultivated and passaged to optimize virus yield in cell culture; (ii) classical genetic reassortment between and the influenza A vaccine donor strain; and (iii) a recombinant reassortant virus comprising the HA and NA genes from and the remaining six genes from PR8 strain was generated using reverse genetics. We assessed the potential of multiple virus seed stocks and selected those with optimum virus growth characteristics for use in further downstream processes. Importantly, to limit the time between identification and isolation of the virus and availability of a virus seed stock for vaccine production, all steps from virus isolation to production of the seed lot were performed in compliance with GMP using the licensed MDCK suspension cell line PF grown in serum-free medium. Most commonly, influenza vaccines are prepared from inactivated virus material that undergoes various purification steps, resulting in the enrichment of the envelope surface proteins HA and NA, which are the major targets of neutralizing antibody response. High virus yields are required to maximize the yield of surface proteins. However, human wild-type influenza A viruses often have a limited ability to replicate in eggs or cell cultures, thus restricting the potential to produce the large amounts of vaccine doses required in a pandemic scenario. To overcome this problem, chimeric viruses are produced which combine the surface proteins HA and NA of the pandemic wild-type isolate with the characteristics of a well growing attenuated influenza donor vaccine strain [e.g., PR8, A/PuertoRico/8/34 (H1N1)]. Classical reassortment is an ideal approach to produce such chimeric viruses. During simultaneous infection and multiplication of the wild-type virus and the vaccine donor strain in a single cell, the genome segments of the two viruses can be randomly exchanged, leading to the emergence of reassortants that possess characteristics of both the wild-type and vaccine donor strains. Using specific antibodies against HA and NA of the donor strain, viruses are subsequently selected that contain genome segments of
3 Strecker et al.: Development of vaccine candidates against 1277 A Wild-type virus B Classical reassortment C Reverse genetics Vaccine donor strain Vaccine donor strain Co-infection and genetic reassortment Six plasmids encoding genes from donor strain M NP NS Two plasmids bearing NA and HA genes from PA PB1 PB2 HA NA Co-transfection of mammalian cells Selection process using neutralized antibodies against the envelope proteins of the vaccine donor strain Reassortant virus Rescued recombinant virus Figure 1 Schematic diagram of vaccine seed strain preparation. (A) Virus propagation of wild-type. (B) Generation of pandemic influenza vaccine seed viruses using classical reassortment. In cells co-infected with an influenza vaccine donor strain and, random combination of genome segments leads to the emergence of reassortants that possess characteristics of both viruses. Ideally, the reassortant virus contains the six genome segments from the donor strain that ensure optimal growth in the cell culture as well as the two segments from the pandemic virus coding for the hemagglutinin and neuraminidase. (C) Generation of recombinant viruses using reverse genetics. Reverse genetics technology allows the generation of infectious influenza viruses using the building block principle with plasmid-based cdna, thus enabling the generation of recombinant viruses with defined genome segments. the vaccine donor strain, thus ensuring optimum growth and genome segments that encode HA and NA from the desired wild-type virus (7, 8). An alternative approach to developing virus seed stocks for influenza vaccines is DNA plasmid-based reverse genetics. This is a straightforward technology that enables the generation of defined chimeric influenza vaccine seed viruses using molecular biological tools (9, 10). Because the process does not require scientists to work directly with potentially highly pathogenic pandemic strains, the safety aspect of reverse genetics makes it a favorable technology for generating recombinant influenza vaccines. This approach uses non-hazardous DNA plasmids containing all eight genome segments of influenza viruses that are transfected into mammalian cells (11, 12). The DNA plasmids serve as intracellular templates for both the synthesis of viral genome segments and the viral proteins that then assemble into infectious viruses that are capable of replication. This technique allows the recovery of infectious viruses directly from cells that are approved for the production of human vaccines (13, 14). Moreover, in the case of genetic engineering through classical cloning procedures, because proteins are denatured and removed during the initial cloning steps and the subsequent preparation of plasmids, plasmid-driven transfection represents an efficient purification step for eliminating potential adventitious agents that may be present in human influenza virus isolates. A full description of our adaptation of reverse genetics technology for generating a potential seed virus in response to the 2009 H1N1 pandemic is presented elsewhere (manuscript in preparation). Our timeline for the development of vaccine seed candidates is shown in Figure 2. We produced a potential seed virus stock based on the cultivation of wild-type isolates within 12 days of receiving the reference virus [influenza A/ California/04/2009 (H1N1)] from the CDC. A recombinant seed virus generated by classical reassortment comprising HA and NA from the pandemic strain was available 6 weeks after initiation. A reverse genetics-based vaccine
4 1278 Strecker et al.: Development of vaccine candidates against Sample arrival -X Virus isolation from clinical material Days Sequencing Virus inoculation and growth Wild-type Virus propagation Reverse genetics Cloning Rescue Virus growth Classical reassortment Reassortment procedures Expansion Figure 2 Timeline for vaccine seed virus production for combating the 2009 pandemic H1N1 influenza virus. strain was rescued and grown within 18 days. All viruses were grown or rescued in the certified MDCK cell line in our BSL-4 laboratory using GMP-compliant procedures that assured the quality of the reference virus for further downstream use in vaccine manufacturing processes. During the initial stages of a pandemic, the use of new, poorly characterized wild-type virus strains to develop a vaccine may pose considerable biosafety risks for scientists and technical personnel. Unfortunately, there are very few vaccine manufacturers in the world who are able to produce vaccines under BSL-3 enhanced biosafety conditions. This means that many vaccine manufacturers are unable to start production until the biocontainment restriction has been downgraded to enhanced BSL-2 level following safety testing in a ferret model and in accordance with national safety regulations. The BSL-4 laboratory in Marburg has the advantage of being able to handle pathogens that require the highest levels of safety precautions. The pathogenic potential of the new virus was not clear as the 2009 pandemic began, so the ability to work safely with the new influenza virus provided a head start in evaluating and testing the purification characteristics of the viral surface antigens HA and NA. Current pandemic vaccines are reassortants comprising the envelope surface genes of the pandemic virus and the remaining genes of an attenuated influenza vaccine donor strain. This method is well established and has been successfully applied in production of seasonal influenza vaccines over the course of several decades. Moreover, this approach allows the selection of well growing viruses that yield large amounts of envelope surface proteins. However, due to the complex screening, selection and genotyping procedures for the desired vaccine strain, this process requires a lead time of up to 2 months from strain identification to the start of vaccine production. In contrast, the development of seed viruses based on reverse genetics can help to significantly reduce the time required to generate influenza virus vaccine seed strains. During our study, we achieved a saving of 3 weeks compared to the classical reassortment method a critical advantage when preparing a pandemic vaccine. However, the use of reverse genetics in human influenza vaccines may have some limitations, including the need for approval of cell lines suitable for efficient virus rescue and vaccine production. Currently, the pharmaceutical company MedImmune holds the intellectual property rights for reverse genetics technology in human influenza vaccine manufacturing. Although MedImmune offers other influenza vaccine manufacturers non-exclusive licenses, the additional cost associated with the payment of royalties may reduce the attractiveness of this methodology to other vaccine manufacturers. However, it is expected that these issues would not restrict the development of reverse genetics-derived vaccines in the case of a severe public health threat. A critical factor in the production of pandemic influenza vaccines is the timely availability of suitable reference seed viruses. During our study, we successfully generated influenza vaccine seed viruses using both classical reassortment and reverse genetics techniques. Fortunately, the 2009 H1N1 influenza pandemic was less severe than anticipated. This pandemic provided a good opportunity to learn how to improve response to future outbreaks of viruses that may be more pathogenic. Our pilot study concluded that alternative strategies are necessary to rapidly produce a safe vaccine strain for mass vaccination purposes. Close collaboration between an academic laboratory and a vaccine manufacturer helped to significantly reduce the time required to produce seed vaccines. The availability of the BSL-4 laboratory during the development of vaccine seed stock enabled immediate response while adhering to the most stringent safety conditions. Moreover, BSL-4 containment ensures seed virus production under conditions that meet the quality assurance requirements necessary for human vaccines. No industrial BSL-4 vaccine manufacturing facilities currently exist. We believe that strategic alliances between academic or government-owned BSL-4 laboratories and vaccine manufacturers will become an essential component in the timely development of effective vaccines during pandemics caused by emerging pathogens.
5 Strecker et al.: Development of vaccine candidates against 1279 Acknowledgments The authors wish to thank all members of the Institute of Virology in Marburg and Novartis Vaccines and Diagnostics, who participated in the development of a vaccine seed virus candidate for combating the 2009 pandemic influenza virus. We are particularly grateful to P.R. Dormitzer for scientific advice, and G. Ludwig and M. Schmidt for expert technical support with regard to BSL-4 procedures. Conflict of interest statement Authors conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. The findings, interpretations and conclusions detailed in this paper are those of the authors. They do not necessarily represent the views of the corresponding affiliates. Research funding: We received financial support from the Philipps- University of Marburg and the Department of Medicine, and Novartis Vaccines and Diagnostics. Employment or leadership: CLB, HT, BR, and UV are employees of or shareholders in Novartis Vaccines and Diagnostics, which manufactures influenza vaccines using MDCK PF cells. Honorarium: None declared. References 1. WHO. World Health Organization guidelines on the use of vaccines and antivirals during influenza pandemics. Geneva: World Health Organization, WHO. Vaccines for pandemic influenza. Geneva: World Health Organization, Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol 1995;69: Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ. Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 1999;98:93 100; discussion Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998;16: Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009;8: Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 1969;41: Fulvini AA, Ramanunninair M, Le J, Pokorny BA, Arroyo JM, Silverman J, et al. Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS One 2011;6:e Neumann G, Kawaoka Y. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cdna. Curr Top Microbiol Immunol 2004;283: Subbarao K, Katz JM. Influenza vaccines generated by reverse genetics. Curr Top Microbiol Immunol 2004;283: Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cdnas. Proc Natl Acad Sci USA 1999;96: Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000;97: Suphaphiphat P, Keiner B, Trusheim H, Crotta S, Tuccino AB, Zhang P, et al. Human RNA polymerase I-driven reverse genetics for influenza a virus in canine cells. J Virol 2010;84: Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol 2008;82:
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update 23 July 2009 Introduction This document updates guidance 1 from the World
More informationChallenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats
Challenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats Susan Dana Jones, Ph.D. BioProcess Technology Consultants, Inc. BIO 2009 Process Zone Theater Atlanta, GE May 20, 2009
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationCristina Cassetti, Ph.D.
NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID Influenza virus DMID
More informationSynthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)
Synthetic Genomics and Its Application to Viral Infectious Diseases Timothy Stockwell (JCVI) David Wentworth (JCVI) Outline Using informatics to predict drift (strain selection) Synthetic Genomics: Preparedness
More informationUpdate of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines
Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines 28 May 2009 Introduction This document updates WHO guidance 1 to national
More informationGuideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture
11 July 2011 EMA/CHMP/BWP/368186/2011 Committee for Human Medicinal Products (CHMP) Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in Draft Agreed by Biologics Working
More informationReassortment of influenza A virus genes linked to PB1 polymerase gene
International Congress Series 1263 (2004) 714 718 Reassortment of influenza A virus genes linked to PB1 polymerase gene Jean C. Downie* www.ics-elsevier.com Centre for Infectious Diseases and Microbiology,
More information1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination
1918 Influenza; Influenza A, H1N1 Basic agent information Section I- Infectious Agent Risk Group: - RG3 Synonym or Cross reference: - Spanish Flu - 1918 Flu - El Grippe Characteristics: - SELECT AGENT
More informationExpedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines
Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines Preamble On 11 June 2009, WHO declared an influenza pandemic caused by influenza A (H1N1) 2009 virus 1. On 13 July 2009, WHO
More informationPandemic Influenza influenza epidemic: realization of a worst-case scenario
Pandemic Influenza October 9, 2006 1918 influenza epidemic: realization of a worst-case scenario First case: Albert Mitchell, Camp Funston, KS, March 11, 1918 Up to 20% of all humans infected 20-50 million
More information(the change introduced is to add a risk assessment, missing from the previous version, for small-scale laboratory work with characterized CVV)
Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines against avian influenza A(H7N9) virus As of 23 May 2013 (replaces version of 10
More informationPandemic Influenza Preparedness
Pandemic Influenza Preparedness Of the many health threats that we are preparing for, this is the one that we know will happen. Bruce G. Gellin, MD, MPH Director, National Vaccine Program Office Department
More informationGuidelines for the safe development and production of vaccines to human pandemic influenza viruses and viruses with pandemic potential
ENGLISH ONLY Guidelines for the safe development and production of vaccines to human pandemic influenza viruses and viruses with pandemic potential Revision of Annex 5 of WHO Technical Report Series WHO
More informationReverse genetic platform for inactivated and live-attenuated influenza vaccine
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 42, No. 2, 116-121, February 2010 Reverse genetic platform for inactivated and live-attenuated influenza vaccine Eun-Ju Jung, Kwang-Hee Lee and Baik Lin Seong
More informationTechnology Overview. Summary
Live Attenuated Influenza Vaccines with Altered NS1 Technology Overview Summary Transformative Technology: Live attenuated influenza vaccines (LAIVs) with precise, genetically stable truncations of the
More informationTITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?
TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important? AUTHORS: Joshua G. Petrie 1, Adam S. Lauring 2,3 AFFILIATIONS: 1 Department of Epidemiology, University of
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationHuman H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry
Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Luc Hessel M.D. Pandemic Influenza Working Group European Vaccine Manufacturers 4th Joint EC/ECDC/WHO Workshop
More informationAvian influenza Avian influenza ("bird flu") and the significance of its transmission to humans
15 January 2004 Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans The disease in birds: impact and control measures Avian influenza is an infectious disease
More informationRESEARCH WITH HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1
Page 1 of 8 RESEARCH WITH HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1 The University of Pittsburgh has developed guidelines to establish a system of education and safeguards to ensure compliance with both the
More informationIFPMA IVS ITF Background Paper The WHO System for Influenza Surveillance and Supply of Viruses for the Standardized Production of Influenza Vaccines
The WHO System for Influenza Surveillance and Supply of Viruses for the Standardized Production of Influenza Vaccines BACKGROUND Chemin Louis-Dunant 15, P.O., Box 195, 1211 Geneva 20, Switzerland Tel:
More informationShould the US develop and Stockpile Vaccines and Antiviral Medications Against. A(H5N1) Avian Flu?
Spring Upshaw Biology Due: 7/7/06 Should the US develop and Stockpile Vaccines and Antiviral Medications Against A(H5N1) Avian Flu? The A(H5N1) avian flu, which has existed since 1997 is lethal in humans
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationActive and Passive Immunization for Avian Influenza Virus Infections
NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of
More informationAn Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationGlobal Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today
Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural
More information100 years of Influenza Pandemic and the prospects for new influenza vaccines
100 years of Influenza Pandemic and the prospects for new influenza vaccines Dr John McCauley Director, WHO Collaborating Centre for Reference and Research on influenza The Francis Crick Institute London
More informationBroadly protective influenza vaccines for pandemic preparedness. Suresh Mittal Department of Comparative Pathobiology Purdue University
Broadly protective influenza vaccines for pandemic preparedness Suresh Mittal Department of Comparative Pathobiology Purdue University Influenza A Virus Orthomyxovirus Consist of s/s (-) sense RNA 8 segments
More informationAnnex 4. Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration
Annex 4 Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration Introduction 156 General considerations 156 Part A. Manufacturing
More informationPlasmid-Driven Formation of Influenza Virus-Like Particles
JOURNAL OF VIROLOGY, Jan. 2000, p. 547 551 Vol. 74, No. 1 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Plasmid-Driven Formation of Influenza Virus-Like
More informationBiosafety and Bioethics
Biosafety and Bioethics Special Challenges of Gain-of Function Experiments and Potential Pandemic Pathogens Marc Lipsitch, D.Phil. Eagleson Lecture, ABSA October 22, 2013 Kansas City Funded by the National
More informationnumbe r Done by Corrected by Doctor
numbe r 5 Done by Mustafa Khader Corrected by Mahdi Sharawi Doctor Ashraf Khasawneh Viral Replication Mechanisms: (Protein Synthesis) 1. Monocistronic Method: All human cells practice the monocistronic
More informationContribution of avian influenza data through OFFLU network
Dr Gounalan Pavade Chargé de Mission, OIE Headquarters Contribution of avian influenza data through OFFLU network Asia-Pacific Workshop on surveillance, prevention and control of zoonotic influenza Paro,
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationph1n1 H3N2: A Novel Influenza Virus Reassortment
ph1n1 H3N2: A Novel Influenza Virus Reassortment Jonathan Gubbay Medical Microbiologist Public Health Laboratory Public Health Ontario June 16, 2011 ph1n1 H3N2 Reassortment: Talk Overview Explain strain
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More informationInfluenza vaccines: present and future
PERSPECTIVE SERIES The future of vaccine design Peter Palese and Adolfo García-Sastre, Series Editors Influenza vaccines: present and future Peter Palese and Adolfo García-Sastre Department of Microbiology,
More informationDevelopment of a Novel Recombinant Influenza Vaccine in Insect Cells
Development of a Novel Recombinant Influenza Vaccine in Insect Cells Clifton McPherson New Cells for New Vaccines II September 18, 2007 cmcpherson@proteinsciences.com New Cell for New Vaccines II Topics:
More informationThe A(H7N9) influenza outbreak in China
Viruses in May, Katoomba, 9 11 May 2013 The A(H7N9) influenza outbreak in China Anne Kelso Director WHO Collaborating Centre for Reference and Research on Influenza Melbourne Influenza in the 21 st century:
More informationWhere Health Care Meets Policy. with Dr. Mike Magee
Where Health Care Meets Policy with Dr. Mike Magee The Threat of Bird Flu Understanding Bird Flu and the Influenza Virus 3 types of the influenza virus: A, B and C reflect differences in the M protein
More informationLesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease
URI CMB 190 Issues in Biotechnology Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease 1. The film Contagion: (A) entirely depicts a situation that could never possibly happen
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 16 February 2006 Doc. Ref.EMEA/CVMP/IWP/46853/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER: MINIMUM
More informationOriginal Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus
Iranian Journal of Virology 2011;5(4): 6-10 2011, Iranian Society for Virology Original Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus
More informationDevelopment of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak, PhD Institute of Experimental Medicine, Saint Petersburg, Russia The
More informationUniversity of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009
University of Colorado Denver Pandemic Preparedness and Response Plan April 30, 2009 UCD Pandemic Preparedness and Response Plan Executive Summary The World Health Organization (WHO) and the Centers for
More informationInfluence of Host Cell Defence during Influenza Vaccine Production in MDCK Cells
Vaccine Technology III, 07 June 2010 Puerto Vallarta/Mexico Influence of Host Cell Defence during Influenza Vaccine Production in MDCK Cells T. Frensing 1, C. Seitz 1, B. Heynisch 2 and U. Reichl 1/2 1
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationAvian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center
Avian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center Definitions: Epidemic The occurrence of cases of an illness in a community or region which
More informationInfluenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
More informationUpdate on influenza monitoring and vaccine development
Update on influenza monitoring and vaccine development Annette Fox WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity 1 Outline Why
More informationRole of Cell Culture Technology in new Vaccine Development
Role of Cell Culture Technology in new Vaccine Development Asst. Prof. Dr.Kanokwan Poomputsa School of Bioresources and Technology King Mongkut s University of Technology Thonburi Outline Introduction
More informationCurrent Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?
Current Vaccines: Progress & Challenges Influenza Vaccine what are the challenges? Professor John S. Tam The Hong Kong Polytechnic University Asia-Pacific Alliance for the Control of Influenza (APACI)
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationThe Veterinary Biological Industry and the Production of Human Pandemic Influenza Vaccines in Mexico
The Veterinary Biological Industry and the Production of Human Pandemic Influenza Vaccines in Mexico Bernardo Lozano, DVM. Laboratorio Avi-Mex, SA de CV WHO-FAO-OIE Consultation Seminar Geneva, Switzerland
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationWORLD HEALTH ORGANIZATION. Smallpox eradication: destruction of Variola virus stocks
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD EB111/5 111th Session 23 December 2002 Provisional agenda item 5.3 Smallpox eradication: destruction of Variola virus stocks Report by the Secretariat 1. The WHO
More informationUnderstanding mortality from pandemic and seasonal influenza
Understanding mortality from pandemic and seasonal influenza Jonathan A. McCullers Associate Member Department of Infectious Diseases St. Jude Children s Research Hospital H1 H2 H3 H4 H5 H6 H7 H8 H9 H10
More informationTechnical and Regulatory Considerations in Rapid Scale-Up of Vaccine Manufacturing Processes
Technical and Regulatory Considerations in Rapid Scale-Up of Vaccine Manufacturing Processes Susan Dana Jones, Ph.D. BioProcess Technology Consultants, Inc. Vaccine Scale up and Manufacturing Conference
More informationGlobal Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme
Global Challenges of Pandemic and Avian Influenza 19 December 2006 Keiji Fukuda Global influenza Programme Summary of Current H5N1 Situation 1997 First known outbreak infecting humans 18 people hospitalized
More informationRequest for Letters of Intent. International Development of H5N1 Influenza Vaccines
Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop
More informationRunning head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1
Running head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1 Electron micrograph of H1N1 Virus (CDC, 2009) Influenza Virus Season Preparedness and Response Patricia Bolivar Walden University Epidemiology
More informationInfluenza: The Threat of a Pandemic
April, 2009 Definitions Epidemic: An increase in disease above what you what would normally expect. Pandemic: A worldwide epidemic 2 What is Influenza? Also called Flu, it is a contagious respiratory illness
More informationHemagglutinin Mutants of Swine Influenza Virus Differing in
INFECTION AND IMMUNITY, Oct. 1979, p. 197-201 0019-9567/79/10-0197/05$02.00/0 Vol. 26, No. 1 Hemagglutinin Mutants of Swine Influenza Virus Differing in Replication Characteristics in Their Natural Host
More informationCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and Research Current Activities Future Directions Washington, DC January 25, 2010 Karen Midthun, MD Acting Director, CBER CBER Our Mission To ensure the safety, purity,
More informationBioterrorism and the Pandemic Potential
Page 1 of 5 Bioterrorism and the Pandemic Potential March 7, 2013 1001 GMT Print 38 35 125 29 Text Size Stratfor By Rebecca Keller Periodic media reports of bird flu, a new SARS-like virus and a case of
More informationAssessment of Influenza Vaccine Production Compatibilities
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza
More informationEngineering Foot-and-Mouth Disease Virus with Improved Properties for the Development of Effective Vaccine Introduction: Materials and methods:
Engineering Foot-and-Mouth Disease Virus with Improved Properties for the Development of Effective Vaccine Haixue Zheng, Fan Yang, Ye Jin, Jianhong Guo, Jijun He, Kaiqi Lian, Zixiang Zhu, Weijun Cao, Lvlv,
More informationINFLUENZA-2 Avian Influenza
INFLUENZA-2 Avian Influenza VL 7 Dec. 9 th 2013 Mohammed El-Khateeb Overview 1. Background Information 2. Origin/History 3. Brief overview of genome structure 4. Geographical Distribution 5. Pandemic Nature
More informationAvian Influenza Virus H7N9. Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences
Avian Influenza Virus H7N9 Dr. Di Liu Network Information Center Institute of Microbiology Chinese Academy of Sciences Avian Influenza Virus RNA virus, Orthomyxoviruses Influenza A virus Eight Gene segments
More informationPage 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect
More informationStockpiling of H5N1 vaccines
Stockpiling of H5N1 vaccines Norbert W. Hehme EVM Influenza Pandemic Working Group EU-Commission Workshop on Stockpiling of Medicinal Products February 21/22, 2008 European Vaccine Manufacturers 1 (EVM)
More informationPUBLIC HEALTH SIGNIFICANCE SEASONAL INFLUENZA AVIAN INFLUENZA SWINE INFLUENZA
INFLUENZA DEFINITION Influenza is an acute highly infectious viral disease characterized by fever, general and respiratory tract catarrhal manifestations. Influenza has 3 Types Seasonal Influenza Avian
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationHousing of Different Infected Mice in the Same Room: How to Prevent Roommate Conflicts? Jocelyn Beaucher, PhD, microbiologist Biosafety Officer
Housing of Different Infected Mice in the Same Room: How to Prevent Roommate Conflicts? Jocelyn Beaucher, PhD, microbiologist Biosafety Officer L Université de Sherbrooke Located in the Eastern Townships,
More informationINFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE
INFLUENZA VIRUS INFLUENZA VIRUS CDC WEBSITE http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm 1 THE IMPACT OF INFLUENZA Deaths: PANDEMICS 1918-19 S p a n is h flu 5 0 0,0 0 0 U S 2 0,0 0 0,0 0 0 w o rld
More informationInfluenza. By Allison Canestaro-Garcia. Disease Etiology:
Influenza By Allison Canestaro-Garcia Disease Etiology: The flu is an infectious disease caused by a subset of viruses of the family Orthomyxoviridae. There are 7 different viruses in this family, four
More informationANALYZING AND MANAGING RISKS IN LIFE SCIENCES RESEARCH
Practical Training Exercise ANALYZING AND MANAGING RISKS IN LIFE SCIENCES RESEARCH Based on the article by Siddique, N. et al. Sequence and phylogenetic analysis of highly pathogenic avian influenza H5N1
More informationStrategies for control of influenza by targeting broadly conserved viral features
Strategies for control of influenza by targeting broadly conserved viral features Forum on Microbial Threats Institute of Medicine June 16, 2004 Suzanne Epstein, Ph.D. Laboratory of Immunology and Developmental
More informationVaccine 30 (2012) Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al h om epa ge:
Vaccine 30 (2012) 7395 7399 Contents lists available at SciVerse ScienceDirect Vaccine jou rn al h om epa ge: www.elsevier.com/locate/vaccine Possible outcomes of reassortment in vivo between wild type
More informationApproaches to Pandemic Influenza Vaccine Preparedness
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza
More informationInfluenza surveillance and pandemic preparedness - a global challenge Anne Kelso
Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso WHO Collaborating Centre for Reference and Research on Influenza Melbourne, Australia Three global health challenges 243
More informationThe role of National Influenza Centres (NICs) during Interpandemic, Pandemic Alert and Pandemic Periods
The role of National Influenza Centres (NICs) during Interpandemic, Pandemic Alert and Pandemic Periods INTRODUCTION National Influenza Centres (NICs) are the backbone of the WHO Global Influenza Surveillance
More informationModeling the Antigenic Evolution of Influenza Viruses from Sequences
Modeling the Antigenic Evolution of Influenza Viruses from Sequences Taijiao Jiang Center of Systems Medicine, Chinese Academy of Medical Sciences Suzhou Institute of Systems Medicine October 8-10, 2015.
More informationVIROLOGY. Engineering Viral Genomes: Retrovirus Vectors
VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed
More information1. Engineering Foot-and-Mouth Disease Viruses with Improved
Engineering Foot-and-Mouth Disease Virus with Improved Properties for the Development of Effective Vaccine Haixue Zheng, Fan Yang, Ye Jin, Jianhong Guo, Jijun He, Lvlv, Xuepeng Cai, Xiangtao Liu, Hong
More information100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness
100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness OCTOBER 16, 2018 SALLY A. HOJVAT M.Sc., Ph.D. Retired as Director of FDA Division of Microbiology Devices,
More informationhemagglutinin and the neuraminidase genes (RNA/recombinant viruses/polyacrylamide gel electrophoresis/genetics)
Proc. Natl. Acad. Sci. USA Vol. 73, No. 6, pp. 242-246, June 976 Microbiology Mapping of the influenza virus genome: Identification of the hemagglutinin and the neuraminidase genes (RNA/recombinant viruses/polyacrylamide
More informationAVIAN FLU BACKGROUND ABOUT THE CAUSE. 2. Is this a form of SARS? No. SARS is caused by a Coronavirus, not an influenza virus.
AVIAN FLU BACKGROUND 1. What is Avian Influenza? Is there only one type of avian flu? Avian influenza, or "bird flu", is a contagious disease of animals caused by Type A flu viruses that normally infect
More information6.2 Pandemic influenza
6.2 Pandemic influenza See Background Paper 6.2 (BP6_2Pandemic.pdf) Background and developments since 2004 The WHO estimates that annual influenza epidemics account for about 3 to 5 million cases of severe
More informationREVIEW Cell-mediated Immunity to Influenza Virus Infections: From the Perspective to the Vaccine Development against Highly Pathogenic Avian Influenza
JARQ 42 (4), 245 249 (2008) http://www.jircas.affrc.go.jp REVIEW : From the Perspective to the Vaccine Development against Highly Pathogenic Avian Influenza Hirokazu HIKONO 1 *, Masaji MASE 2, Satoko WATANABE
More informationOur T cell epitope test service offers you:
Our T cell epitope test service offers you: high throughput peptide discovery fast lead-finding maximum of epitopes in a minimum of blood saving effort and costs on developing your own platforms custom-made
More informationThe H5N1 Influenza Controversy: Implications for Science Governance. Larry Kerr, PhD Senior Advisor to the Director for Global Biological Threats
The H5N1 Influenza Controversy: Implications for Science Governance Larry Kerr, PhD Senior Advisor to the Director for Global Biological Threats Palais des Nations Room Geneva, Switzerland 17 July 2012
More informationChapter 5. Virus isolation and identification of measles and rubella in cell culture
Chapter 5. Virus isolation and identification of measles and rubella in cell culture In this chapter: 5.1. Recommended cell line for measles and rubella virus isolation 5.2. Propagation of Vero/hSLAM cells
More informationProduction of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety risk assessment
1 Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses Interim biosafety risk assessment DEPARTMENT OF COMMUNICABLE DISEASE SURVEILLANCE AND
More informationInfluenza Virus Genotypes Circulating In Central Greece During And Vaccine Strain Match
ISPUB.COM The Internet Journal of Microbiology Volume 13 Number 1 Influenza Virus Genotypes Circulating In Central Greece During 2012-2014 And Vaccine Strain Match E Plakokefalos, A Vontas, Z Florou, G
More informationQuality, safety and standards for poliomyelitis vaccines
Quality, safety and standards for poliomyelitis vaccines 7 th WHO/UNICEF consultation Geneva, 30 October 2008 Jackie Fournier-Caruana, WHO/QSS 1 Expert Committee on Biological Standardization The ECBS
More informationWhat is influenza virus? 13,000 base RNA genome: 1/ the size of the human genome
What is influenza virus? 13,000 base RNA genome: 1/246153 the size of the human genome CDC Principles of Virology, 4e Neumann et al. Nature. 2009. Influenza virus is one of the most deadly viral pathogens
More informationSupplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T
More information